Close Menu

Cancer Biomarkers

News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.

The company will initiate a Phase I/II clinical trial in patients with HER2-positive solid tumors later this year.

The decision is based on pooled single-arm trial data demonstrating the agent's ability to prolong progression-free survival and shrink patients' tumors.

At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.

The framework is meant to guide healthcare providers in facilitating prostate cancer genetic testing in a timely and responsible way, the researchers said.

The firms will jointly study the combination, and Sanofi will have an exclusivity period to negotiate the in-licensing of KN026, contingent on certain milestones.

The Amgen-sponsored Phase Ib study is evaluating the combination in patients with advanced solid tumors characterized by KRAS G12C mutations.

PLX8394 is currently being studied in a Phase I/II trial of BRAF-mutated tumors, and Novellus plans to use its next-generation sequencing-based FACT assay to help further develop the drug.

With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.

The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.  

Results show population screening can pick up risky BRCA1/2 mutations in men and women from Ashkenazi Jewish populations in the US, though engagement challenges remain.

Pages